Please assess the completion status of the following clinical trial:

Trial Title: Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 40-80 years (inclusive)~2. Kellgren-Lawrence grading I-III, as determined by American College of Rheumatology (ACR) criteria for osteoarthritis of the knee~3. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score of 7-17 in the study knee even if treated with chronic doses of non steroidal anti-inflammatory drugs~4. Having provided informed consent~Exclusion Criteria:~1. With previous surgery of articular fracture, ligament reconstruction, meniscal reconstruction, and knee arthroplasty on the target knee joint~2. With previous intra-articular intervention on the target knee joint within past 3 months (e.g. steroid, anaesthetic, sodium hyaluronate)~3. Known or suspected infection of the target knee joint~4. Ascertained hypersensitivity to any component used in the study~5. Administered with systemic anti-inflammatory drugs (e.g. non-steroidal anti-inflammatory drug or steroid ) or topical anti-inflammatory drugs on target knee within 7 days prior to administration in the study~6. With serious prior or ongoing medical conditions (e.g. concomitant illness such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition, alcoholism, drug abuse), medical history, physical findings, , or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the patient~7. With any evidence of malignant disease with life expectancy of less than 1 year~8. Pregnant or lactating women or planning to be pregnant during the study period~9. With body mass index (BMI) greater or equal to 35 kg/m2~10. With joint diseases except knee osteoarthritis considered by investigator not eligible to enter the study~11. With known history of human immunodeficiency virus (HIV) infection.~12. Judged to be not applicable to this study by investigator such as difficulty of follow-up observation~13. With any other serious diseases/medical history considered by the investigator not in the condition to enter the trial~14. Having participated other investigational study within 4 weeks of entering this study~15. With known history of claustrophobia~16. Having any existing active/inactive implanted medical devices, such as cardiac pacemaker, cochlear, intracranial vascular clips or neurostimulator, etc...~17. Having any existing metallic intraocular foreign body

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Elixcyte 8mL (Type: EXPERIMENTAL): ADSC 6.4\*10\^7 cells, allogeneic injection, one time injection on Day 1
- Hya Joint Plus (Type: ACTIVE_COMPARATOR): Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc., one time injection on Day 1
- Elixcyte 4mL (Type: EXPERIMENTAL): ADSC 3.2\*10\^7 cells, allogeneic injection, one time injection on Day 1
- Elixcyte 2mL (Type: EXPERIMENTAL): ADSC 1.6\*10\^7 cells, allogeneic injection, one time injection on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete